ILMN Stock Set to Gain From Expansion of TruSight Oncology Portfolio

Zacks11-20 20:07

Illumina, Inc. ILMN is expanding its TruSight Oncology portfolio with a new version of its flagship cancer research assay, currently under development. The TruSight Oncology 500 v2 (TSO 500 v2) to ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2484111465?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/XuMJ_dsQDMqLc73Q7JGcxA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/cd9fa2ca3125c2741152b27cc2930bff","is_english":true,"pubTime":"2024-11-20 20:07","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2484111465","market":"us","top_or_hot":-1,"title":"ILMN Stock Set to Gain From Expansion of TruSight Oncology Portfolio","media":"Zacks","content":"<div>\n<p>Illumina, Inc. ILMN is expanding its TruSight Oncology portfolio with a new version of its flagship cancer research assay, currently under development. The TruSight Oncology 500 v2 (TSO 500 v2) to ...</p>\n\n<a href=\"https://finance.yahoo.com/news/ilmn-stock-set-gain-expansion-120700559.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ILMN Stock Set to Gain From Expansion of TruSight Oncology Portfolio</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nILMN Stock Set to Gain From Expansion of TruSight Oncology Portfolio\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-20 20:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/ilmn-stock-set-gain-expansion-120700559.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Illumina, Inc. ILMN is expanding its TruSight Oncology portfolio with a new version of its flagship cancer research assay, currently under development. The TruSight Oncology 500 v2 (TSO 500 v2) to ...</p>\n\n<a href=\"https://finance.yahoo.com/news/ilmn-stock-set-gain-expansion-120700559.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0012050646.USD","symbol_name":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" (USD) INC AV","start_time":0,"source_url":"https://finance.yahoo.com/news/ilmn-stock-set-gain-expansion-120700559.html","article_id":"2484111465","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/XuMJ_dsQDMqLc73Q7JGcxA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/cd9fa2ca3125c2741152b27cc2930bff"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2484111465","pubTimestamp":1732104420,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Illumina, Inc.ILMN is expanding its TruSight Oncology portfolio with a new version of its flagship cancer research assay, currently under development. The TruSight Oncology 500 v2  to enable comprehensive genomic profiling  of tumors will be presented at the annual meeting of the Association of Molecular Pathology in Vancouver, British Columbia, on Nov. 21.One of the customers having early access to TSO 500 v2 emphasized the relevance of the assay’s new features to clinical research laboratories and positively affected time to results, quality of results and the processing of challenging tissue samples. The global release of the new assay is expected in mid-2025.After the announcement yesterday, ILMN shares climbed 3.3%, finishing at $135. Illumina's oncology portfolio has evolved over time to fit customers' diverse needs for versatility and scalability. The TSO portfolio encompasses research-use-only  andin-vitrodiagnostic  solutions across a range of low, mid and high-throughput inst","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0012050646.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" (USD) INC AV","BK4534":"瑞士信贷持仓","BK4585":"ETF&股票定投概念","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","IE0009354923.USD":"JANUS HENDERSON US VENTURE \"A2\" (USD) ACC","IE00BLDYK493.USD":"NEUBERGER BERMAN US SMALL CAP \"A\" (USD) INC","BK4535":"淡马锡持仓","BK4082":"医疗保健设备","BK4121":"生命科学工具和服务","PEN":"Penumbra Inc","BK4588":"碎股","BK4198":"医疗保健用品","IE00B64QTZ34.USD":"NEUBERGER BERMAN US SMALL CAP \"A\" (USD) ACC","GMED":"Globus Medical Inc","ILMN":"Illumina","LU2065732104.USD":"ALLSPRING (LUX) WF GLOBAL SMALL CAP EQUITY \"I\" (USD) ACC","LU0205193047.USD":"SCHRODER ISF US SMALL & MID-CAP EQUITY \"A\" (USD)  ACC","LU0106261612.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" ACC","BK4548":"巴美列捷福持仓","LU0205194284.USD":"SCHRODER ISF US SMALL & MID-CAP EQUITY \"A\" (USD) INC AV","HAE":"美国血液技术"},"translate_title":"ILMN股票将从TruSight肿瘤产品组合的扩张中受益","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PEN":1,"GMED":1,"ILMN":1,"HAE":0.9},"content_text":"Illumina, Inc. ILMN is expanding its TruSight Oncology portfolio with a new version of its flagship cancer research assay, currently under development. The TruSight Oncology 500 v2 (TSO 500 v2) to enable comprehensive genomic profiling (CGP) of tumors will be presented at the annual meeting of the Association of Molecular Pathology in Vancouver, British Columbia, on Nov. 21.\nOne of the customers having early access to TSO 500 v2 emphasized the relevance of the assay’s new features to clinical research laboratories and positively affected time to results, quality of results and the processing of challenging tissue samples. The global release of the new assay is expected in mid-2025.\nPredicting ILMN Stock Movement Following the News\nAfter the announcement yesterday, ILMN shares climbed 3.3%, finishing at $135. Illumina's oncology portfolio has evolved over time to fit customers' diverse needs for versatility and scalability. The TSO portfolio encompasses research-use-only (TSO 500 products) and in-vitro diagnostic (TSO Comprehensive) solutions across a range of low, mid and high-throughput instrumentation. We expect the latest development to positively boost market sentiment toward ILMN stock.\nIllumina currently has a market capitalization of $20.74 billion. The company’s earnings in 2024 are expected to surge nearly 343% compared to the industry’s 17.8% growth. In the trailing four quarters, it delivered an earnings beat of 432.76%, on average,\nKey Features of Illumina’s Latest Solution\nTSO 500 v2 assesses hundreds of genes across all variant classes and immuno-oncology biomarkers in a single assay from one sample to facilitate therapy selection research. It features faster turnaround time, reduced hands-on time, sensitive variant calling and improved coverage of difficult genomic regions.\nImage Source: Zacks Investment Research\nThe assay includes the gold-standard Myriad Genomic Instability Score to determine homologous recombination deficiency status for all samples. The new kit configurations have 50% less packaging and 70% fewer tubes and boast improved usability. TSO 500 v2 also has integrated and automated data analysis, from sequencers to insights, supported with DRAGEN secondary analysis and Illumina Connected Insights or Velsera's Clinical Genomics Workspace. Other features of the assay include broad platform compatibility and automation methods that are available with flexible batch sizes.\nIndustry Prospects Favoring Illumina\nPer a Research report, the global tumor profiling market was valued at $11 billion in 2023 and is expected to witness a compound annual rate of 10.3% by 2030. The rising number of cancer cases and precision oncology, tailoring therapies to a tumor's unique genetic makeup, relies heavily on tumor profiling. Technological advancements are making tumor profiling faster, more accurate and more affordable.\nMore Updates From Illumina\nIn the same release, the company announced that its TSO Comprehensive kits are now available to ship. In August 2024, Illumina achieved the FDA’s approval for the TSO Comprehensive test and its first two companion diagnostic indications. The single test interrogates more than 500 genes to profile a patient's solid tumor, helping increase the likelihood of identifying an immuno-oncology biomarker or clinically actionable biomarkers that enable targeted therapy options or clinical trial enrollment.\nILMN Stock Price Performance\nIn the past year, ILMN shares have rallied 38.5% against the industry’s decline of 0.9%.\nILMN’s Zacks Rank and Key Picks\nIllumina currently carries a Zacks Rank #3 (Hold).\nSome better-ranked stocks in the broader medical space are Penumbra PEN, Haemonetics HAE and Globus Medical GMED, each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.\nPenumbra’s shares have risen 0.7% in the past year. Estimates for the company’s 2024 earnings per share have jumped 8.1% to $2.79 in the past 30 days. PEN’s earnings beat estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 10.54%. In the last reported quarter, it posted an earnings surprise of 23.19%.\nEstimates for Haemonetics’ fiscal 2025 earnings per share have jumped 0.4% to $4.59 in the past 30 days. Shares of the company have rallied 2.3% in the past year compared with the industry’s growth of 22.8%. HAE’s earnings surpassed estimates in three of the trailing four quarters and missed in one, the average surprise being 2.82%. In the last reported quarter, it delivered an earnings surprise of 2.75%.\nEstimates for Globus Medical’s 2024 earnings per share have increased 0.4% to $2.95 in the past 30 days. Shares of the company have surged 83.6% in the past year compared to the industry’s 15.4% growth. GMED’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 17.65%. In the last reported quarter, it delivered an earnings surprise of 27.69%.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nIllumina, Inc. (ILMN) : Free Stock Analysis Report\nHaemonetics Corporation (HAE) : Free Stock Analysis Report\nGlobus Medical, Inc. (GMED) : Free Stock Analysis Report\nPenumbra, Inc. (PEN) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"Product Release","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2484111465"}